potassium channel; hyperpolarization; sweat secretion; thermoregulation CUTANEOUS VASODILATION and sweating are important to maintain a stable core body temperature during heat stress in humans. Although both adrenergic and cholinergic sympathetic nerves innervate cutaneous vessels and sweat glands, cholinergic nerves primarily mediate cutaneous vasodilation and sweating during whole body heat stress via postsynaptic receptor activation induced by acetylcholine and/or neuropeptides (18, 40) . As for acetylcholine, it activates muscarinic receptors and triggers signal transduction in the intracellular spaces, and K ϩ channels are involved in this process associated with the regulation of cutaneous vasodilation (2, 16) and sweating (38) . Activation of K ϩ channels accompanies K ϩ efflux and thus hyperpolarization in the vascular smooth muscle cells, which reduces the intracellular Ca 2ϩ bioavailability that results in vasodilation. In addition, hyperpolarization associated with the activation of K ϩ channels occurring in the sweat glands ensures an electrochemical driving force for Cl Ϫ efflux into the lumen side of sweat gland, facilitating the production of sweat. However, which type(s) of K ϩ channels are specifically involved in the regulation of cholinergic cutaneous vasodilation and sweating remains to be elucidated.
Studies have identified a role for Ca 2ϩ -activated K ϩ (K Ca ) (2) and ATP-sensitive K ϩ (K ATP ) (16) channels in the regulation of cholinergic cutaneous vasodilation. However, to the best of our knowledge, no study has investigated whether voltage-gated K ϩ (K V ) channels may also be involved in this response. Given that K V channels have been shown to modulate cholinergic vasodilation under in vitro conditions in nonhuman species (9, 13) , they may also play an important role in humans under in vivo conditions. As for the cholinergic sweating, whereas an in vitro study by Shamsuddin et al. (38) showed that K ϩ channels modulate cholinergic sweating, they found no roles for a number of specific K ϩ channels including K Ca , K ATP , and K V (i.e., K V7.1 ) channels. However, they did not test all subtypes of K V channels, leaving the possibility that K V channels (other than K V7.1 ) may contribute to cholinergic sweating. Despite our growing knowledge on the role of K ϩ channels in the regulation of cholinergic sweating, there remains a significant gap in our understanding of the roles of K Ca , K ATP , and K V channels in cholinergic sweating under in vivo conditions in humans.
Thus the purpose of the present study was to evaluate roles of K Ca , K ATP , and K V channels in the regulation of cholinergic cutaneous vasodilation and sweating in resting normothermic humans in vivo. We evaluated the hypothesis that both K Ca and K ATP channels as well as K V channels contribute to the regulation of cholinergic cutaneous vasodilation, whereas only K V channels are involved in the regulation of cholinergic sweating. In the present study, as opposed to utilizing acetylcholine to induce cholinergic cutaneous vasodilation and sweating, we employed methacholine, which is a known acetylcholine mimetic. To minimize the effects of nicotinic receptor activation on the cutaneous vasodilatory and sweating response and to isolate the muscarinic response, we chose to use methacholine given that it primarily activates muscarinic receptors (as opposed to acetylcholine which can activate both muscarinic and nicotinic receptors) (32) .
MATERIALS AND METHODS
Ethical approval. The current study was approved by the University of Ottawa Health Sciences and Science Research Ethics Board, which is in accordance with the guidelines set forth by the Declaration of Helsinki. Verbal and written informed consent was obtained from all volunteers before their participation in the study.
Subjects. Thirteen physically active young males participated in this study. Mean (ϮSD) body mass, height, and age for the participants were the following: 78.3 Ϯ 14.0 kg, 1.75 Ϯ 0.06 m, and 24 Ϯ 5 yr, respectively. All subjects were screened on a separate day before participating in the experimental session. Participants with a history of cystic fibrosis transmembrane conductance regulator mutations, skin disorders, hypertension, heart disease, diabetes, autonomic disorders, and/or cigarette smoking were excluded from the study. No subjects were taking prescription medications.
Experimental design. All subjects were instructed to abstain from taking over-the-counter medications (including nonsteroidal anti-inflammatory agents and vitamins) for at least 48 h before the experimental session, as well as alcohol and caffeine consumption at least 12 h prior. Subjects refrained from performing intense exercise the day before the study. On the day of the experiment, participants were restricted from consuming food 2 h before and throughout the study. We did not control for the start time of the experiment; however, there was no clear difference in the pattern of response between the morning and afternoon period of the day. Upon arrival, the subjects voided their bladder, thereafter body mass was measured using a digital weight scale platform (model CBU150X, Mettler Toledo, OH) with a weighing terminal (model IND560, Mettler Toledo). The subject's body height was also measured using an eye-level physician stadiometer (model 2391, Detecto Scale, Webb City, MO). Subjects were then seated in a semi-recumbent position in a thermoneutral room (ϳ23°C) and equipped with four intradermal microdialysis fibers (30 kDa cutoff, 10 mm membrane) (MD2000, Bioanalytical Systems, West Lafayette, IN) placed on the dorsal side of the left forearm within the dermal layer of the skin. With the use of aseptic technique, a 25-gauge needle was first inserted into the unanesthetized skin and then a microdialysis fiber was threaded through the lumen of the needle. The needle was subsequently withdrawn leaving only the fiber in place. The entry and exit points for the fibers were separated by ϳ2.5 cm with a separation of 4.0 cm between the four fiber insertion points. All fibers were then secured with surgical tape.
Approximately 10 min after the completion of fiber insertion, the four microdialysis fibers were continuously perfused with 1) lactated Ringer (Control, Baxter, Deerfield, IL), 2) 50 mM tetraethylammonium (Sigma-Aldrich, St. Louis, MO), a nonspecific K Ca channel blocker, 3) 5 mM glybenclamide (Sigma-Aldrich), a specific KATP channel blocker, and 4) 10 mM 4-aminopyridine (Sigma-Aldrich), a nonspecific KV channel blocker. The concentrations of tetraethylammonium (3, 4, 22, 24) and glybenclamide (22) were determined based on previous studies in which an intradermal microdialysis fiber was implanted in human skin. A previous study confirmed that intradermal administration of 50 mM tetraethylammonium via microdialysis specifically targets KCa channels with minimal influence on other K ϩ channels (3). We did not use specific large conductance KCa channel blockers such as charybdotoxin and iberiotoxin as they are toxic to humans (33) . The concentration of 4-aminopyridine (10 mM) was determined based on our pilot work wherein concentrations of 1, 5, 10, 20, 50, and 100 mM of 4-aminopyridine were tested. We found that Ն20 mM of 4-aminopyridine caused numbness and/or tingling as well as higher basal cutaneous blood flow, which were sustained Ͼ2 h after the initiation of 4-aminopyridine infusion. We determine that 10 mM of 4-aminopyridine is the highest dose that can be used without inducing some degree of numbness and tingling in the local skin area. While 10 mM of 4-aminopyridine caused a higher cutaneous blood flow in the present study, this response subsided with a prolonged (i.e., 82 Ϯ 3 min) resting period before the start of the experimental phase of the protocol. To dissolve water-insoluble glybenclamide into lactated Ringer solution, we needed to add dimethyl sulfoxide (Sigma-Aldrich) and sodium hydroxide (Sigma-Aldrich), resulting in a final solution with 5% dimethyl sulfoxide and a pH of 11. To account for the slight increase in baseline cutaneous blood flow associated with dimethyl sulfoxide (4, 20, 39) as well as the potential influence of dimethyl sulfoxide and higher pH (11) on cholinergic cutaneous vasodilation and sweating responses, all four solutions (Control, tetraethylammonium, glybenclamide, and 4-aminopyridine) were dissolved in lactated Ringer containing 5% dimethyl sulfoxide with the pH adjusted to 11. Each drug was continuously perfused at a rate of 4.0 l/min using a microinfusion pump (model 4004, CMA Microdialysis, Solna, Sweden). Perfusion continued for the entire experimental protocol until the procedure for maximal cutaneous vasodilation began (see below).
After the 82 Ϯ 3 min resting period of each K ϩ channel blocker administration, 10 min of baseline data (Baseline) was collected. Subsequently, each microdialysis fiber was perfused with methacholine (Sigma-Aldrich) in an ascending manner with five different concentrations of 0.0125, 0.25, 5, 100, and 2,000 mM at a rate of 4.0 l/min (each for 25 min) in combination with the site-specific pharmacological agents with 5% dimethyl sulfoxide and a pH of 11. After the last infusion of methacholine (2,000 mM) was completed, 50 mM of sodium nitroprusside (Sigma-Aldrich) was administered at each microdialysis site at a rate of 6.0 l/min until a stable plateau for cutaneous blood flow was achieved, which we defined as maximal cutaneous blood flow (20 -30 min). Occasionally, the increase in cutaneous blood flow during methacholine administration (i.e., 5-2,000 mM) was greater than that achieved by sodium nitroprusside, which is in accordance with previous reports (10, 23) . In that case, the highest cutaneous blood flow during methacholine administration was considered as maximal cutaneous blood flow.
Measurements. Cutaneous red blood cell flux (expressed in perfusion units) was locally measured as an index of cutaneous blood flow at a sampling rate of 32 Hz using laser-Doppler flowmetry (PeriFlux System 5000, Perimed, Stockholm, Sweden). Integrated laser-Doppler flowmetry probes with a 7-laser array (model 413, Perimed) were housed in the center of each sweat capsule over each microdialysis fiber for simultaneous measurement of both local forearm sweat rate and cutaneous red blood cell flux. Manual auscultation was performed using a mercury column sphygmomanometer (Baumanometer Standby model, WA Baum, Copiague, NY) to obtain blood pressures every 10 -15 min. Mean arterial pressure was calculated from diastolic arterial pressure plus one-third the difference between systolic and diastolic pressures (i.e., pulse pressure). Cutaneous vascular conductance (CVC) was evaluated as cutaneous red blood cell flux divided by mean arterial pressure.
A sweat capsule covering an area of 1.1 cm 2 specifically designed for use with an intradermal microdialysis probe (27) was placed directly over the center of each microdialysis membrane. The sweat capsules were secured to the skin with adhesive rings and topical skin glue (Collodion HV, Mavidon Medical products, Lake Worth, FL). Dry compressed air in gas tanks located in the thermoneutral room (ϳ23°C) was supplied to each capsule at a rate of 0.20 l/min, while water content of the effluent air from the sweat capsule was measured with high-precision dew point mirrors (model 473, RH systems, Albuquerque, NM). Long vinyl tubes were used for connections between the gas tank and the sweat capsule, and between the sweat capsule and the dew point mirror. Local forearm sweat rate was measured continuously (5 s sampling rate) and calculated from the difference in water content between influent and effluent air multiplied by the flow rate and normalized for the skin surface area under the capsule (mg·min Ϫ1 ·cm Ϫ2 ). Data analysis. CVC data were presented in maximal percent (%max), which minimizes the effect of site-to-site heterogeneity at the level of cutaneous blood flow (29) . Maximal absolute CVC, which is used to calculate %max, was obtained during sodium nitroprusside administration or during higher doses of methacholine administration. All values used for data analysis (CVC and sweat rate) were obtained by averaging values over the last 5 min of each stage (i.e., Baseline, 0.0125, 0.25, 5, 100, 2,000 mM of methacholine). We calculated the change (⌬) in CVC and sweat rate from Baseline to each methacholine concentration. We also evaluated the highest ⌬CVC and ⌬sweat rate achieved throughout methacholine administration protocol (defined as Peak). Furthermore, ⌬CVC from 100 to 2,000 mM of methacholine administration was evaluated at each site.
Statistical analysis. All statistical tests were performed using the software package SPSS 23 for Windows (IBM, Armonk, NY). ⌬CVC (%max) and ⌬sweat rate (mg·min Ϫ1 ·cm Ϫ2 ) from Baseline were analyzed using a two-way repeated measures analysis of variance with repeated factors of treatment site (four levels: Control, KCa channel blocker, KATP channel blocker, KV channel blocker) and stage (seven levels: Baseline, 5 doses of methacholine, Peak). One-way repeated measures analysis of variance was employed to analyze CVC (%max) and sweat rate (mg·min Ϫ1 ·cm Ϫ2 ) obtained at Baseline as well as maximal absolute CVC (perfusion units/mmHg) with a repeated factor of treatment site (four levels: Control, KCa channel blocker, KATP channel blocker, KV channel blocker). When a significant interaction or main effect was detected, post hoc multiple comparisons were conducted using the Student's paired two-tailed t-tests. P values for the multiple comparisons were adjusted using a modified Bonferroni test (i.e., Hochberg's procedure) (15) . The level of significance for all analyses was set at P Յ 0.05. All values are reported with a mean Ϯ 95% confidence interval. The confidence intervals at 95% were calculated as 1.96 ϫ means Ϯ SE.
RESULTS
Baseline. The administration of the K Ca channel blocker reduced CVC relative to Control (Fig. 1A) . However, when compared with Control, no effect on sweating was measured for any of the K ϩ channel blocked sites (Fig. 1B) . During methacholine administration. When compared with the Control, the K Ca channel blocker attenuated ⌬CVC at 0.0125 and 5 mM of methacholine, whereas K ATP and K V channel blockers decreased ⌬CVC at 100 mM of methacholine only (Fig. 2) . Furthermore, the K V channel blocker attenuated ⌬sweat rate at 2,000 mM of methacholine relative to Control (Fig. 3) . The infusion of the K V channel blocker also attenuated ⌬CVC and ⌬sweat rate assessed at Peak compared with Control (Fig. 4) . Finally, K ATP and K V channel blockers augmented ⌬CVC and ⌬sweat rate measured at 0.25 and/or 5 mM of methacholine (Figs. 2 and 3) .
During 100 mM of methacholine administration, CVC at the Control site reached ϳ80%max, which subsequently decreased during 2,000 mM of methacholine administration (Fig. 5) .
However, this reduction in CVC was not observed when each K ϩ channel was simultaneously blocked (Fig. 5) . Maximal absolute CVC. Maximal absolute CVC (perfusion units/mmHg) was comparable between the four sites (Control, 1.46 Ϯ 0.28; K Ca channel blocker, 1.57 Ϯ 0.33; K ATP channel blocker, 1.37 Ϯ 0.22; K V channel blocker, 1.23 Ϯ 0.18) (P ϭ 0.30 for a main effect of treatment site).
DISCUSSION
We show that K Ca and K ATP channels contribute to cholinergic cutaneous blood flow regulation, which is in accordance with previous reports. Importantly, we are the first to demonstrate that K V channels also play an important role in the cholinergic regulation of cutaneous perfusion, whereas only the K V channels modulate the cholinergic sweating response in normothermic resting humans.
Cutaneous vascular response. Our findings demonstrate that K V channels do not modulate basal cutaneous vascular tone (i.e., as assessed during the Baseline period) under normothermic conditions (Fig. 1A) . By contrast, consistent with previous studies (4, 11), we confirmed the contribution of K Ca channels in defining basal cutaneous vascular tone (Fig. 1A) . In contrast to a previous report by Hojs et al. (16), we did not observe a role for K ATP channels in this response (Fig. 1A) . However, given the reported contribution of K ATP channels to basal vascular tone is relatively small (ϳ10%) under a normothermic state, we can generally conclude that K ATP channels do not have a major role in the regulation of basal cutaneous vascular tone.
A key finding of our study was the observation that K V channels contribute to cholinergic cutaneous vasodilation elicited by 100 mM of methacholine (Fig. 2) . Since K V channels also contribute to CVC observed at Peak (Fig. 4A) , K V channels appear to have an important role in mediating higher levels of skin perfusion (e.g., ϳ80%max of CVC as presented in Fig. 4A ). Furthermore, we also show that both K Ca (at 0.0125 and 5 mM of methacholine) and K ATP (at 100 mM of methacholine) channels contribute to cholinergic cutaneous vasodilation (Fig. 2) . These findings for K Ca and K ATP channels are consistent with previous studies using acetylcholine (2, 16) . Taken together, our findings demonstrate that K Ca , K ATP , and K V channels are important factors in the regulation of cholinergic cutaneous vasodilation in normothermic resting humans. In general, K ϩ channels are located on the vascular smooth muscle cells, and their activation induces hyperpolarization and a reduction of intracellular Ca 2ϩ bioavailability thereby inducing vasorelaxation. Some K ϩ channels are also present on the vascular endothelial cells (e.g., small and intermediate conductance K Ca channels), and hyperpolarization associated with the activation of endothelial K ϩ channels can spread from the endothelium to vascular smooth muscle cells via gap junctions, thereby resulting in vasodilation (12, 26) . Also, activation of endothelial K ϩ channels causes K ϩ efflux into the extracellular space, which in turn can activate Na ϩ -K ϩ -ATPase and/or inwardly rectifying K ϩ channels ultimately causing hyperpolarization of vascular smooth muscle cells and therefore vasodilation (7, 12, 31) . Further studies are required to elucidate the precise locations of each K ϩ channel subtype in human cutaneous vessels and how each K ϩ channel contributes to cholinergic cutaneous vasodilation.
At the Control site, a decline in CVC was measured between 100 to 2,000 mM of methacholine infusion despite an increase in cholinergic stimulation (Figs. 2 and 5 ), a pattern of response that we have previously observed (10, 14) . This response appears not to be associated with nitric oxide synthase and cyclooxygenase, as we previously showed that inhibition of both nitric oxide synthase and cyclooxygenase did not influence the attenuation (10) . However, in the current study, the decline of CVC from 100 to 2,000 mM of methacholine was abolished when blocking either K Ca , K ATP , or K V channels (Fig. 5) . Thus, taken together, it is plausible to conclude that this aforementioned attenuation of cutaneous vasodilation may be related to a deactivation of K ϩ channels, which causes depolarization associated with reduced K ϩ efflux, ultimately resulting in vasoconstriction.
Although our results suggest roles of K Ca , K ATP , and K V channels in the regulation of cholinergic cutaneous vasodilation, a large portion of cutaneous vasodilation observed during high doses of methacholine administration (100 and 2,000 mM) was induced independently of these channels (Figs. 2 and  4A) . Thus other factor(s) is/are likely involved. Indeed, we previously showed that nitric oxide synthase, but not cyclooxygenase, contributes to methacholine-induced cutaneous vasodilation (10). It is possible that K ϩ channel-dependent cutaneous vasodilation observed during cholinergic stimulation may be in part or in whole induced by nitric oxide produced from nitric oxide synthase, as nitric oxide can activate several K ϩ channels including K Ca (1, 30) , K ATP (16) , and K V (17) channels. However, this potential mechanism requires further evaluation.
Sweating. K ϩ is known to be involved in electrolyte transport within the sweat duct (34, 35) . Furthermore, the importance of K ϩ channels for cholinergic sweating has been demonstrated in vitro (38) . However, until the present study, the specific K ϩ channels responsible for cholinergic sweating had not been examined. In this study, we show for the first time that K V channels contribute to cholinergic sweating in humans in vivo (Figs. 3 and 4B) . Recently, an in vitro study by Shamsuddin et al. (38) reported that K V7.1 (one of the many K V channels) did not influence cholinergic sweating. Thus other K V channels are likely involved in cholinergic sweating in humans in vivo such as K V1 , K V2 , and/or K V3 . Future studies are required to establish their respective roles.
Our novel observation of a role for K V channels in the regulation of sweating provides important insight into how cholinergic sweating occurs. During muscarinic receptor activation by cholinergic agent, depolarization occurs in the sweat gland (36) , which may be associated with increases in intracellular Ca 2ϩ through inositol trisphosphate (IP 3 )-dependent mechanisms (21) or Ca 2ϩ influx (28) . This depolarization may activate K V channels, causing hyperpolarization associated with K ϩ efflux, ensuring an electrochemical driving force for Cl Ϫ efflux into the lumen side of sweat gland. This Cl Ϫ efflux can subsequently cause depolarization, which can activate K V channels, allowing continuous Cl Ϫ efflux and thus sweat secretion separately and/or in collaboration with other important factors including Na-K-Cl cotransporter and Na ϩ -K ϩ -ATPase. We also found that blocking K Ca and K ATP channels did not attenuate methacholine-induced sweating (Fig. 3) , which indicates that cholinergic sweating is not mediated via the activation of these channels. This is consistent with previous in vitro findings by Shamsuddin et al. (38) . However, given that Ca 2ϩ has been shown to be a key ion mediating sweat secretion both in vitro (37) and in vivo (28) , it would seem counterintuitive that we showed no role of K Ca channels. It is possible that increases in Ca 2ϩ during cholinergic activation contribute to sweat secretion through K ϩ channel-independent pathways. As proposed by Wilson et al. (41) , Ca 2ϩ may play a role in sweat secretion through Ca 2ϩ -activated Cl Ϫ channels. In support of this mechanism, a recent study by Ertongur-Fauth et al. (8) revealed that one of the Ca 2ϩ -activated Cl Ϫ channels, anoctamin 1 (ANO1), also known as transmembrane member 16A (TMEM16A), appears to be involved in the Ca 2ϩ -dependent Cl Ϫ secretion in the human sweat gland in vitro. In addition, another Ca 2ϩ -activated Cl Ϫ channel, bestrophin 2 (Best 2), has been shown to contribute to sweat secretion as demonstrated in a mice model in vivo (6) .
Considerations. We employed a solution containing 5% dimethyl sulfoxide with a pH of 11 to dissolve glybenclamide, a water-insoluble compound. We do not know how this adjustment made to the glybenclamide solution influenced cholinergic cutaneous vasodilation and sweating. However, by design, all solutions used in the current study had 5% dimethyl sulfoxide and a pH of 11. Therefore, any difference in CVC and sweat rate observed in the present study appears to be due to the blockade of the various specific K ϩ channels. As a first step, we evaluated a single role of each K ϩ channel in cholinergic cutaneous vasodilation and sweating. We do not know if and how K ϩ channels interact with other pathways in mediating cholinergic cutaneous vasodilation and sweating. Previous studies have shown that nitric oxide synthase contributes to cholinergic cutaneous vasodilation (10) and that Ca 2ϩ is involved in cholinergic sweating (28) . Elucidating the potential interactions between K ϩ channels and other pathways (e.g., nitric oxide synthase, Ca 2ϩ ) is an important next step. Unexpectedly, ⌬CVC and ⌬sweat rate in response to lower doses of methacholine (0.25 and 5 mM) were higher at the sites treated with K ATP or K V channel blockade compared with the Control site (Figs. 2 and 3) . We do not know the exact mechanism(s) underpinning this response, but blockade of K ATP or K V channels might sensitize muscarinic receptors located on both cutaneous vessels and sweat glands, augmenting cholinergic cutaneous vasodilation and sweating. While this is an interesting observation, further studies are required to advance our understanding of the physiological implication of this response.
Perspectives and Significance
Human eccrine sweating during heat stress is governed exclusively by the sympathetic cholinergic system (5, 19, 25) . Thus our observations of an involvement of K V channels in cholinergic sweating support a role for K V channels in thermal sweating. In addition, cholinergic mechanisms contribute to changes in cutaneous vascular tone during whole body heat stress (19) . As such, our results demonstrating that K Ca , K ATP , and K V channels contribute to cholinergic cutaneous vasodilation support the possibility that these K ϩ channels may also contribute to cutaneous vasodilation as elicited by whole body heating. Future studies evaluating if, and the extent to which, each K ϩ channel contributes to cutaneous vasodilation and sweating during heat stress are warranted.
In conclusion, we show that K Ca , K ATP , and K V channels all contribute to cholinergic cutaneous vasodilation, whereas K V channels contribute to cholinergic sweating in normothermic resting humans.
